CLINICAL_TRIALS trial_result · 2021-04-19

Clinical Trial Update: Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis [Phase 2]

Phase IIb dose-ranging study in moderate to severe rheumatoid arthritis has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: CSL Behring | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2021-04-19